20,000 Shares in Centessa Pharmaceuticals PLC Sponsored ADR $CNTA Acquired by Torno Capital LLC

Torno Capital LLC purchased a new position in Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) in the 1st quarter, Holdings Channel reports. The institutional investor purchased 20,000 shares of the company’s stock, valued at approximately $794,000. Centessa Pharmaceuticals accounts for 0.1% of Torno Capital LLC’s investment portfolio, making the stock its 18th biggest holding.

A number of other institutional investors have also added to or reduced their stakes in the stock. SG Americas Securities LLC raised its position in shares of Centessa Pharmaceuticals by 1,017.7% during the fourth quarter. SG Americas Securities LLC now owns 263,625 shares of the company’s stock valued at $6,593,000 after buying an additional 240,039 shares during the last quarter. Royce & Associates LP boosted its position in shares of Centessa Pharmaceuticals by 46.7% during the fourth quarter. Royce & Associates LP now owns 362,873 shares of the company’s stock worth $9,075,000 after acquiring an additional 115,486 shares during the last quarter. Sofinnova Investments Inc. purchased a new position in Centessa Pharmaceuticals during the fourth quarter valued at $27,618,000. B. Metzler seel. Sohn & Co. AG purchased a new position in Centessa Pharmaceuticals during the fourth quarter valued at $961,000. Finally, GSA Capital Partners LLP increased its holdings in Centessa Pharmaceuticals by 76.5% in the 4th quarter. GSA Capital Partners LLP now owns 33,104 shares of the company’s stock valued at $828,000 after acquiring an additional 14,343 shares during the last quarter. 82.01% of the stock is owned by hedge funds and other institutional investors.

Centessa Pharmaceuticals Stock Performance

Shares of NASDAQ:CNTA opened at $40.50 on Tuesday. Centessa Pharmaceuticals PLC Sponsored ADR has a 52 week low of $12.74 and a 52 week high of $40.56. The stock has a market capitalization of $6.27 billion, a P/E ratio of -22.63 and a beta of 1.11. The firm has a fifty day simple moving average of $40.16 and a two-hundred day simple moving average of $33.89. The company has a quick ratio of 9.53, a current ratio of 9.53 and a debt-to-equity ratio of 0.23.

Centessa Pharmaceuticals (NASDAQ:CNTA) last posted its earnings results on Tuesday, May 5th. The company reported ($0.52) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.14). On average, analysts expect that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.65 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have commented on CNTA. Weiss Ratings reiterated a “sell (d-)” rating on shares of Centessa Pharmaceuticals in a research note on Monday, April 20th. Leerink Partners cut Centessa Pharmaceuticals from an “outperform” rating to a “hold” rating and lifted their target price for the stock from $36.00 to $40.00 in a report on Wednesday, April 1st. Guggenheim downgraded Centessa Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, April 2nd. Lifesci Capital lowered Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, April 1st. Finally, Wells Fargo & Company downgraded Centessa Pharmaceuticals from an “overweight” rating to an “equal weight” rating and lifted their price objective for the stock from $35.00 to $42.00 in a research note on Monday, April 20th. Four equities research analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $41.33.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.